STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
Noa Biran, MD, delves into the phase II STOMP study, highlighting selinexor’s efficacy with various backbones like pomalidomide, carfilzomib, daratumumab, and reviews dosing strategies and proactive management of associated toxicities.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
Now Viewing
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Related Videos
